|drug870||Placebo: Emtricitabine/tenofovir disoproxil Placebo Wiki||1.00|
|drug1147||The standard Macintosh laryngoscope Wiki||1.00|
|drug404||Emtricitabine/tenofovir disoproxil Wiki||1.00|
|drug1146||The Vie Scope laryngoscope Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.06|
|D018352||Coronavirus Infections NIH||0.05|
There is one clinical trial.
Healthcare workers are particularly at risk of SARS-CoV-2. This study aims to assess the efficacy of a daily single dose of tenofovir disoproxil fumarate (TDF) (245 mg)/ Emtricitabine (FTC) (200 mg), a daily single dose of hydroxychloroquine (HC) (200 mg), a daily single dose of TDF (245 mg)/FTC (200 mg) plus HC (200 mg) versus placebo, during 12 weeks in: (1) reducing the incidence of symptomatic disease and (2) reducing clinical severity COVID-19 among hospital healthcare workers aged 18 to 70 years in public and private hospitals in Spain.
Description: assessed by: No symptoms Mild symptoms: general malaise, fever, cough, myalgia, asthenia. Moderate symptoms: mild symptoms plus shortness of breath, Severe symptoms: mild symptoms plus respiratory insufficiency that requires admission in intensive care unit and mechanical ventilationMeasure: Severity of disease in confirmed infected participants of SARS-CoV-2 (COVID-19) Time: 12 weeks